MedWatch

With launches on the way in the US and EU, MC2 turns attention to the rest of its pipeline

Over the next 12 months, MC2 Therapeutics will start three new clinical studies with the follow-up drugs to Wynzora, which will soon be launched in the US and Europe.

Photo: MC2 Therapeutics / PR

The launch of psoriasis drug Wyzora alongside Epi Health marks the beginning of a new era for MC2 Therapeutics.

The biotech firm, which recently founded its own organization in the US, wants to expand its product range. This is why it has worked on several drug candidates alongside the development of Wynzora, products the company can now allocate more resources to, says Jesper J. Lange, CEO of MC2 Therapeutics.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs